- Home
- VMD vs LCTX Comparison
VMD vs LCTX Comparison
Compare VMD & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- LCTX
- Stock Information
- Founded
- VMD 2006
- LCTX 1990
- Country
- VMD United States
- LCTX United States
- Employees
- VMD N/A
- LCTX N/A
- Industry
- VMD
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VMD
- LCTX Health Care
- Exchange
- VMD Nasdaq
- LCTX Nasdaq
- Market Cap
- VMD 280.4M
- LCTX 274.0M
- IPO Year
- VMD N/A
- LCTX N/A
- Fundamental
- Price
- VMD $6.86
- LCTX $1.73
- Analyst Decision
- VMD
- LCTX Strong Buy
- Analyst Count
- VMD 0
- LCTX 4
- Target Price
- VMD N/A
- LCTX $4.25
- AVG Volume (30 Days)
- VMD 167.2K
- LCTX 1.7M
- Earning Date
- VMD 11-05-2025
- LCTX 11-13-2025
- Dividend Yield
- VMD N/A
- LCTX N/A
- EPS Growth
- VMD 47.14
- LCTX N/A
- EPS
- VMD 0.34
- LCTX N/A
- Revenue
- VMD $240,884,000.00
- LCTX $10,914,000.00
- Revenue This Year
- VMD $19.22
- LCTX N/A
- Revenue Next Year
- VMD $17.51
- LCTX $176.00
- P/E Ratio
- VMD $20.27
- LCTX N/A
- Revenue Growth
- VMD 17.11
- LCTX 76.43
- 52 Week Low
- VMD $5.93
- LCTX $0.37
- 52 Week High
- VMD $9.81
- LCTX $1.85
- Technical
- Relative Strength Index (RSI)
- VMD 50.59
- LCTX 58.93
- Support Level
- VMD $6.66
- LCTX $1.53
- Resistance Level
- VMD $7.10
- LCTX $1.72
- Average True Range (ATR)
- VMD 0.17
- LCTX 0.11
- MACD
- VMD 0.01
- LCTX -0.02
- Stochastic Oscillator
- VMD 45.45
- LCTX 62.50
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.